Synthetic lethality in TNBC mediated by an anti-Trop-2 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), when combined with paclitaxel or the PARP inhibitor, olaparib

被引：0
|
作者：
Goldenberg, D. M. [1 ]
Cardillo, T. M. [1 ]
Govindan, S. V. [1 ]
Zalath, M. [1 ]
Arrojo, R. [1 ]
Sharkey, R. M. [1 ]
机构：
[1] Immunomedics Inc, Morris Plains, NJ USA
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P6-15-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-15-02
引用
收藏
页数：2
相关论文
共 36 条
  • [21] Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer
    Cardillo, Thomas M.
    Sharkey, Robert M.
    Rossi, Diane L.
    Arrojo, Roberto
    Mostafa, Ali A.
    Goldenberg, David M.
    CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3405 - 3415
  • [22] Characterization of an anti-Trop-2-SN-38 antibody-drug conjugate (IMMU-132) with potent activity against solid cancers.
    Goldenberg, David M.
    Rossi, Edmund A.
    Govindan, Serengulam V.
    Cardillo, Thomas M.
    McBride, William J.
    Zalath, Maria
    Terracina, Gaby
    Trisal, Preeti
    Sharkey, Robert M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan
    Goldenberg, David M.
    Sharkey, Robert M.
    MABS, 2019, 11 (06) : 987 - 995
  • [24] Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results
    Bardia, Aditya
    Vahdat, Linda T.
    Diamond, Jennifer
    Kalinsky, Kevin
    O'Shaughnessy, Joyce
    Moroose, Rebecca L.
    Isakoff, Steven J.
    Tolaney, Sara M.
    Santin, Alessandro D.
    Abramson, Vandana
    Shah, Nikita C.
    Govindan, Serengulam V.
    Maliakal, Pius
    Sharkey, Robert M.
    Wegener, William A.
    Goldenberg, David M.
    Mayer, Ingrid A.
    CANCER RESEARCH, 2018, 78 (04)
  • [25] Therapy of Advanced Metastatic Lung Cancers with an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132: Interim Phase II Clinical Results
    Camidge, D. R.
    Starodub, Aleander N.
    Ocean, Allyson
    Messersmith, Wells A.
    Bardia, Aditya
    Thomas, Sajeve S.
    Masters, Gregory
    Heist, Rebecca
    Maliakal, Pius
    Govindan, Serengulam
    Sharkey, Robert M.
    Wilhelm, Francois E.
    Goldenberg, David M.
    Guarino, Michael J.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S173 - S173
  • [26] Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
    Bardia, A.
    Messersmith, W. A.
    Kio, E. A.
    Berlin, J. D.
    Vahdat, L.
    Masters, G. A.
    Moroose, R.
    Santin, A. D.
    Kalinsky, K.
    Picozzi, V
    O'Shaughnessy, J.
    Gray, J. E.
    Komiya, T.
    Lang, J. M.
    Chang, J. C.
    Starodub, A.
    Goldenberg, D. M.
    Sharkey, R. M.
    Maliakal, P.
    Hong, Q.
    Wegener, W. A.
    Goswami, T.
    Ocean, A. J.
    ANNALS OF ONCOLOGY, 2021, 32 (06) : 746 - 756
  • [27] Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers
    Chang, Chien-Hsing
    Wang, Yang
    Zalath, Maria
    Liu, Donglin
    Cardillo, Thomas M.
    Goldenberg, David M.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (08) : 1910 - 1919
  • [28] Treatment of high Trop-2-expressing triple-negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
    Cardillo, Thomas M.
    Mostafa, Ali A.
    Rossi, Diane L.
    Liu, Donglin
    Chang, Chien-Hsing
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER RESEARCH, 2017, 77
  • [29] Phase I/II trial of IMMU-132 (isactuzumab govitecan), an anti-Trop-2-SN-38 antibody drug conjugate (ADC): Results in patients with metastatic gastrointestinal (GI) cancers.
    Starodub, Alexander
    Ocean, Allyson J.
    Messersmith, Wells A.
    Picozzi, Vincent J.
    Guarino, Michael J.
    Thomas, Sajeve Samuel
    Bardia, Aditya
    Shah, Manish A.
    Govindan, Serengulam V.
    Maliakal, Pius P.
    Wegener, William A.
    Hamburger, Steven A.
    Sharkey, Robert M.
    Goldenberg, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [30] Safety, efficacy, and pharmacokinetics of a new humanized anti-Trop-2 antibody-SN-38 conjugate (IMMU-132) for the treatment of diverse epithelial cancers: Phase I clinical experience.
    Starodub, Alexander N.
    Ocean, Allyson J.
    Guarino, Michael J.
    Chuang, Ellen
    Shah, Manish A.
    Tagawa, Scott
    Picozzi, Vincent J.
    Thomas, Sajeve S.
    Maliakal, Pius P.
    Wegener, William A.
    Sharkey, Robert M.
    Govindan, Serengulam V.
    Goldenberg, David M.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
1234